

Durham Region Health Department FAX about...



For Health Care Professionals

COVID-19 Therapeutic Clinic Update

A COVID-19 Therapeutic Clinic opened on January 26, 2022 at Lakeridge Health's Ajax Pickering Hospital (580 Harwood Avenue South). The clinic provides treatment with antiviral medication (including Paxlovid [nirmatrelvir/ritonavir] and sotrovimab) to adults with mild to moderate COVID-19 symptoms who are eligible and at high risk of progressing to serious illness. The clinic is available by appointment only and will take referrals from COVID-19 Assessment Centres, Cold and Flu Clinics, and community providers, working with them to determine the most appropriate treatment for eligible individuals.

Identifying Clients at Higher Risk

Based on updated guidance from the Ontario COVID-19 Science Advisory Table, individuals at higher risk (based on age, vaccination status, and risk factors) can be referred to the COVID-19 Therapeutic Clinic.

	Number of COVID-19 vaccines			Risk Factors
Age (years)	0 doses	1 or 2 doses	3+ doses	• BMI >30 kg/m2
<20	Higher Risk if 3 or more risk factors	Standard Risk	Standard Risk	 Diabetes Heart disease, hypertension, or CHF Chronic lung disease Cerebral palsy Intellectual Disability Sickle Cell Disease Moderate-severe kidney disease (eGFR <60mL/min) Moderate-severe liver disease (Child-Pugh class B or C cirrhosis)
20-39	Higher Risk if 3 or more risk factors	Higher Risk if 3 or more risk factors	Standard Risk	
40-69	Higher Risk if 1 or more risk factors	Higher Risk if 3 or more risk factors	Standard Risk	
>70	Higher Risk	Higher Risk if 1 or more risk factors	Higher Risk if 3 or more risk factors	
Pregnant	Higher Risk	Standard Risk	Standard Risk	
Immuno- compromised*	Higher Risk	Higher Risk	Higher Risk	

*Immunocompromised includes - Solid organ or bone marrow transplant, CAR T-cell therapy, Anti-CD 20, anti-TNF, other immunosuppressive biologic agent, Alkylating agents, anti-metabolites, Advanced or untreated HIV, Active therapy for solid tumor or hematologic malignancy, Surveillance for lymphoid malignancy (e.g. CLL), Moderate-severe congenital immunodeficiency, Chronic corticosteroids (equivalent of prednisone 20mg/day for 2 or more weeks)



Accessing the COVID-19 Therapeutic Clinic

Those individuals listed above as **higher risk** should seek testing at a COVID-19 Assessment Centre by completing the form at covid19swab.lh.ca or by calling 905-721-4842 if unable to book online.

Community providers can refer to the COVID-19 Therapeutic Clinic by faxing the intake form (attached) to 905-831-8326. The clinic runs Monday to Sunday 1000 to 1800hrs. Clients need to have a positive COVID-19 test (PCR, RAT, or pending) and symptom onset must be within the last 7 days.

Reminder that testing and diagnosis early after symptom onset is necessary to be eligible for treatment.

For questions regarding clinic operation and logistics please contact ctc@lh.ca.

March 16, 2022





COVID-19 Therapeutic Clinic

580 Harwood Avenue S. Ajax

Telephone: 905-985-4721 Fax: 905-831-8326

Email: CTC@lh.ca

Hours of operation: Monday to Sunday 1000 to 1800

Name:
DOB:
HCN:
Phone #:
Email:

PLEASE ENSURE THE PATIENT HAS A FULL LIST OF MEDICATIONS, INHALERS, AND SUPPLEMENTS AVAILABLE TO REVIEW WITH THE CLINIC

CLINIC EXCLUSIONS (refer to SHN monoclonal clinic instead)

- On dialysis or eGFR <30
- >5 days symptoms, but less than 7 days

<u>CL</u>	<u>INIC INCLUSIONS (check all that apply)</u>						
	Date of positive covid test: / / Test: RAT PCR Pending						
	Date of symptom onset (must be <7 days): /						
	☐ Willing to take COVID therapy and to travel or have someone travel to the clinic nearest you to receive therap						
	AND at least one criteria under A, B, C or D below:						
	A) Immunocompromised or immunosuppressed individuals not expected to mount an adequate immune						
	response to COVID-19 vaccination or SARS-CoV-2 infection (regardless of vaccine status) defined as						
	one of the following:						
	Active treatment for solid tumor and hematologic malignancies (including individuals with lymphoid						
	malignancies who are being monitored without active treatment) (Specify:).						
	Receipt of solid-organ transplant and taking immunosuppresive therapy (Specify:).						
	Receipt of chimeric antigen receptor (CAR)-T-cell or hematopoietic stem cell transplant (within 2 years of						
	transplantation or taking immunosuppression therapy).						
	Moderate or severe primary immunodeficiency (e.g. DiGeorge syndrome, Wiskott-Aldrich syndrome, common variable immunodeficiency, Good's syndrome, hyper IgE syndrome) (Specify:).						
	Advanced or untreated HIV infection.						
	Active treatment with high-dose corticosteroids (i.e. equal or greater than 20 mg prednisone or equivalent						
	per day when administered for equal or greater than 2 weeks).						
	Active treatment with alkylating agents, antimetabolites (including methotrexate), transplant-related						
	immunosuppressive drugs, cancer chemotherapeutic agents classified as severly immunosuppressive,						
	tumor-necrosis factor (TNF) blockers or other biologic agents that are immunosuppressive or						
	immunomodulatory (Specify:).						





COVID-19 Therapeutic Clinic

	B) Unvaccinated individuals (0 doses of any COVID—Age equal or greater than 70 years Age equal or greater than 40 with 1 or more risk factor Age equal or greater than 12 with 3 or more risk factor Pregnant	rs*			
C) Individuals who have had 1 or 2 doses of a COVID-19 vaccine Age equal or greater than 70 with 1 or more risk factors* Age equal or greater than 20 with 3 or more risk factors*					
D) Individuals who have had 3 doses of a COVID-19 vaccine Age equal or greater than 70 with 3 or more risk factors*					
Ind Me Bla Asi Ob Car Cer	of Risk Factors: igenous (First Nations, Inuit, or Metis) mbers of Racialized Communities (e.g. Arab, Middle Easteck, Latin American, Indo-Caribbean, South Asian, Southeran, or West Asian) esity (Body mass index equal or greater than 30 kg/m2) rdiovascular Disease (including hypertension) rebral Palsy ronic Kidney Disease (eGFR less than 60 mL/min/1.73 m2 lysis)	cystic fibrosis and asthma) Diabetes Mellitus Intellectual Disability Sickle Cell Disease			
Wa	s patient prescribed COVID therapy?: □ Fl	uvoxamine □ Budesonide □ No			
Re	ferring Physician (Print Name)	Referring Physician Billing No.			
Re	ferring Physician (Signature)	Location of Referral			
		Date			